Dupilumab (Dupixent)
Customize your policy alerts
Sign up for Peach State Health Plan Policy GA.PMN.32 alerts
Get alerted when Policy GA.PMN.32 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing limits, prescriber qualifications, and approval durations for Dupilumab (Dupixent) across FDA‑approved and selected off‑label indications for Peach State Health Plan Medicaid members.
Changed Atopic Dermatitis initial criteria from requiring 2 TCS to One TCS.
Changed CRSwNP initial criteria from requiring two intranasal corticosteroids to one intranasal corticosteroid.
Changed Prurigo Nodularis criteria from requiring both WI-NRS and total lesion count to requiring one or the other.
Updated approved indication to include pediatric patients aged 12 years and older for CRSwNP.
Added newly approved COPD indication to criteria.
For prurigo nodularis, updated itch scale language to 'Numeric rating scale > 7 (0–10) (e.g., Peak Pruritus NRS)'.
Added new indication for CSU per updated prescribing information.
For COPD, revised postbronchodilator FEV1 requirement from 30-70% to 20-80% to align with Nucala.
Added new indication for bullous pemphigoid (BP) per updated prescribing information and P&T-approved clinical guidance.
Extended initial approval duration from 6 to 12 months for all labeled indications as maintenance therapy for chronic conditions.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.